Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?

Bibliography

• Kolhe NV, Stevens PE, Crowe AV, Case mix, outcome and activity for patients with severe acute kidney injury during the first 24 hours after admission to an adult, general critical care unit: application of predictive models from a secondary analysis of the ICNARC Case Mix Programme database. Crit Care 2008;12(Suppl 1):S2
   PubMedGoogle Scholar
• Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin 2006;22(2):329-45, vii
   PubMed Web of Science ®Google Scholar
• Stevenson JM, Patel JH, Churchwell MD, Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs 2008;31(12):1027-34
   PubMed Web of Science ®Google Scholar
• Vilay AM, Churchwell MD, Mueller BA. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 2008;12(6):235
   PubMedGoogle Scholar
• Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37(3):840-51
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007;11(3):R68
   PubMedGoogle Scholar
• Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008;23(5):1569-74
   PubMed Web of Science ®Google Scholar
• Thakar CVMDF, Christianson AMS, Freyberg RMS, Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med 2009;37(9):2552-8
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429(6990):464-8
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348(6):529-37
   PubMed Web of Science ®Google Scholar
• Macphee IA, Fredericks S, Mohamed M, Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005;79(4):499-502
   PubMed Web of Science ®Google Scholar
• MacPhee IA, Fredericks S, Tai T, The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004;4(6):914-9
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S, Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77
   PubMed Web of Science ®Google Scholar
• Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology 1985;62(3):310-24
   PubMed Web of Science ®Google Scholar
• Glass PS, Jhaveri RM, Ginsberg B, Ossey K. Evaluation of flumazenil for reversing the effects of midazolam-induced conscious sedation or general anesthesia. South Med J 1993;86(11):1238-47
   PubMed Web of Science ®Google Scholar
• Kupietzky A, Houpt MI. Midazolam: a review of its use for conscious sedation of children. Pediatr Dent 1993;15(4):237-41
   PubMedGoogle Scholar
• Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. Current status of benzodiazepines. N Engl J Med 1983;309(6):354-8
   PubMed Web of Science ®Google Scholar
• Cole SG, Brozinsky S, Isenberg JI. Midazolam, a new more potent benzodiazepine, compared with diazepam: a randomized, double-blind study of preendoscopic sedatives. Gastrointest Endosc 1983;29(3):219-22
   PubMed Web of Science ®Google Scholar
• Milgrom P, Beirne OR, Fiset L, The safety and efficacy of outpatient midazolam intravenous sedation for oral surgery with and without fentanyl. Anesth Prog 1993;40(3):57-62
   PubMedGoogle Scholar
• van der Bijl P, Roelofse JA. Propofol and midazolam for conscious sedation in a mentally retarded dental patient. Anesth Prog 1992;39(1-2):36-7
   PubMedGoogle Scholar
• Wright SW, Chudnofsky CR, Dronen SC, Comparison of midazolam and diazepam for conscious sedation in the emergency department. Ann Emerg Med 1993;22(2):201-5
   PubMed Web of Science ®Google Scholar
• Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 1984;28(6):519-43
   PubMed Web of Science ®Google Scholar
• Kanto J, Allonen H. Pharmacokinetics and the sedative effect of midazolam. Int J Clin Pharmacol Ther Toxicol 1983;21(9):460-3
   PubMedGoogle Scholar
• Baraff LJ. Conscious sedation of children. Ann Emerg Med 1994;24(6):1170-2
   PubMed Web of Science ®Google Scholar
• Hartgraves PM, Primosch RE. An evaluation of oral and nasal midazolam for pediatric dental sedation. ASDC J Dent Child 1994;61(3):175-81
   PubMedGoogle Scholar
• Taylor JW, Simon KB. Possible intramuscular midazolam-associated cardiorespiratory arrest and death. DICP 1990;24(7-8):695-7
   PubMedGoogle Scholar
• Fragen RJ. Pharmacokinetics and pharmacodynamics of midazolam given via continuous i ntravenous infusion in intensive care units. Clin Ther 1997;19(3):405-19, discussion 367-8
   PubMed Web of Science ®Google Scholar
• Bauer TM, Ritz R, Haberthur C, Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995;346(8968):145-7
   PubMed Web of Science ®Google Scholar
• Tuk B, van Oostenbruggen MF, Herben VM, Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther 1999;289(2):1067-74
   PubMed Web of Science ®Google Scholar
• Mandema JW, Tuk B, van Steveninck AL, Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51(6):715-28
   PubMed Web of Science ®Google Scholar
• Johnson TN, Rostami-Hodjegan A, Goddard JM, Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002;89(3):428-37
   PubMed Web of Science ®Google Scholar
• Paulussen A, Lavrijsen K, Bohets H, Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000;10(5):415-24
   PubMedGoogle Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
   PubMed Web of Science ®Google Scholar
• Brian WR, Sari MA, Iwasaki M, Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990;29(51):11280-92
   PubMed Web of Science ®Google Scholar
• Dahl ML, Yue QY, Roh HK, Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5(3):159-64
   PubMedGoogle Scholar
• Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005;77(6):458-67
   PubMed Web of Science ®Google Scholar
• Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001;59(2):386-92
   PubMed Web of Science ®Google Scholar
• Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000;260(1-2):13-23
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Thummel KE. CYP3A. Lippincott-Raven, New York; 2000
   Google Scholar
• Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003;31(12):1526-30
   PubMed Web of Science ®Google Scholar
• Kupferschmidt HH, Ha HR, Ziegler WH, Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58(1):20-8
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430
   PubMed Web of Science ®Google Scholar
• Ball SE, Scatina J, Kao J, Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66(3):288-94
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Hermann R, Huennemeyer A, Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther 2006;79(4):339-49
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-91
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling AL, Quigley SD, Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62(1):162-72
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27(4):383-91
   PubMed Web of Science ®Google Scholar
• Floyd MD, Gervasini G, Masica AL, Genotype- phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003;13(10):595-606
   PubMedGoogle Scholar
• Hustert E, Haberl M, Burk O, The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11(9):773-9
   PubMedGoogle Scholar
• Kivisto KT, Niemi M, Schaeffeler E, Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14(8):523-5
   PubMedGoogle Scholar
• Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58(3):521-90
   PubMed Web of Science ®Google Scholar
• Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 2005;15(6):415-21
   PubMed Web of Science ®Google Scholar
• Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001;29(12):1644-51
   PubMed Web of Science ®Google Scholar
• Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4(4):171-84
   PubMedGoogle Scholar
• Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 2003;73(3):153-8
   PubMed Web of Science ®Google Scholar
• Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993;71(2):282-90
   PubMed Web of Science ®Google Scholar
• Autschbach R, Falk V, Lange H, Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass. Thorac Cardiovasc Surg 1996;44(2):76-80
   PubMed Web of Science ®Google Scholar
• Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P- glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 2002;72(5):524-35
   PubMed Web of Science ®Google Scholar
• Gorski JC, Jones DR, Haehner-Daniels BD, The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64(2):133-43
   PubMed Web of Science ®Google Scholar
• Thummel KE, O'Shea D, Paine MF, Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59(5):491-502
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD, Podoll TD, Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271(1):549-56
   PubMed Web of Science ®Google Scholar
• Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30(5):653-61
   PubMed Web of Science ®Google Scholar
• Chow PKH, Yu W-K, Soo K-C, Chan STF. The measurement of liver blood flow: a review of experimental and clinical methods. J Surg Res 2003;112(1):1-11
   PubMed Web of Science ®Google Scholar
• Swart EL, van der Hoven B, Groeneveld AB, Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol 2002;53(2):133-9
   PubMed Web of Science ®Google Scholar
• Nolin TD, Frye RF, Le P, ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 2009;20(10):2269-76
   PubMed Web of Science ®Google Scholar
• Nath A, Atkins W. Principal component analysis of CYP2C9 and CYP3A4 probe substrate/inhibitor panels. Drug Metab Dispos 2008;36(11):2151-5
   PubMed Web of Science ®Google Scholar
• Kinirons MT, O'Shea D, Kim RB, Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999;66(3):224-31
   PubMed Web of Science ®Google Scholar
• Rivory LP, Slaviero K, Seale JP, Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000;6(9):3480-5
   PubMed Web of Science ®Google Scholar
• Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet 2001;40(3):151-8
   PubMed Web of Science ®Google Scholar
• Wanwimolruk S, Paine MF, Pusek SN, Watkins PB. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4? Br J Clin Pharmacol 2002;54(6):643-51
   PubMed Web of Science ®Google Scholar
• Watkins PB, Murray SA, Winkelman LG, Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989;83(2):688-97
   PubMed Web of Science ®Google Scholar
• McCrea J, Prueksaritanont T, Gertz B, Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999;39(12):1212-20
   PubMed Web of Science ®Google Scholar
• Moriyama S, Okamoto K, Tabira Y, Evaluation of oxygen consumption and resting energy expenditure in critically ill patients with systemic inflammatory response syndrome. Crit Care Med 1999;27(10):2133-6
   PubMed Web of Science ®Google Scholar
• Brandi LSMD, Bertolini RMD, Santini LMD, Cavani SMD. Effects of ventilator resetting on indirect calorimetry measurement in the critically ill surgical patient. Crit Care Med 1999;27(3):531-9
   PubMed Web of Science ®Google Scholar
• Kurnik D, Wood AJJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity[ast]. Clin Pharmacol Ther 2006;80(3):228-34
   PubMed Web of Science ®Google Scholar
• Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol 2010;6(1):69-74
   Google Scholar
• Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007;19(3):223-7
   PubMed Web of Science ®Google Scholar
• Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 2005;78(5):529-39
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis[ast]. Clin Pharmacol Ther 2004;76(5):452-66
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47(9):1643-53
   PubMed Web of Science ®Google Scholar
• Lin YS, Lockwood GF, Graham MA, In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001;11(9):781-91
   PubMedGoogle Scholar
• Penzak SR, Busse KH, Robertson SM, Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol 2008;48(6):671-80
   PubMed Web of Science ®Google Scholar
• Krupka E, Venisse N, Lafay C, Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers. Eur J Clin Pharmacol 2006;62(8):653-9
   PubMed Web of Science ®Google Scholar
• Kirwan CJ, Lee T, Holt DW, Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 2009;35(7):1271-5
   PubMed Web of Science ®Google Scholar
• Leber HW, Gleumes L, Schutterle G. Enzyme induction in the uremic liver. Kidney Int Suppl 1978;14(8):S43-8
   Google Scholar
• Leber HW, Schutterle G. Oxidative drug metabolism in liver microsomes from uremic rats. Kidney Int 1972;2(3):152-8
   PubMed Web of Science ®Google Scholar
• Patterson SE, Cohn VH. Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol 1984;33(5):711-6
   PubMed Web of Science ®Google Scholar
• Van Peer AP, Belpaire FM. Hepatic oxidative drug metabolism in rats with experimental renal failure. Arch Int Pharmacodyn Ther 1977;228(2):180-3
   PubMedGoogle Scholar
• Uchida N, Kurata N, Shimada K, Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 1995;68(4):431-9
   PubMedGoogle Scholar
• Leblond F, Guevin C, Demers C, Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001;12(2):326-32
   PubMed Web of Science ®Google Scholar
• Leblond FA, Petrucci M, Dube P, Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2002;13(6):1579-85
   PubMedGoogle Scholar
• Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000;28(11):1317-20
   PubMed Web of Science ®Google Scholar
• Guevin C, Michaud J, Naud J, Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002;137(7):1039-46
   PubMed Web of Science ®Google Scholar
• Dowling TC, Briglia AE, Fink JC, Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003;73(5):427-34
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003;16(1):45-50
   PubMed Web of Science ®Google Scholar
• Taburet A, Vincent I, Perello L, Impairment of drug biotransformation in renal disease: an in vitro model. Am Soc Clin Pharmacol Ther 1996;59:136
   Google Scholar
• Michaud J, Dube P, Naud J, Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005;144(8):1067-77
   PubMed Web of Science ®Google Scholar
• Terao N, Shen DD. Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. J Pharmacol Exp Ther 1983;227(2):295-301
   PubMed Web of Science ®Google Scholar
• Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther 1985;233(2):277-84
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36(1):296-327
   PubMed Web of Science ®Google Scholar